Tirzepatide is a revolutionary dual GIP/GLP-1 receptor agonist peptide that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The recommended dose may range from 1 to 5 mL, depending on the concentration of each vitamin component and the desired therapeutic effect
While both appear in regenerative research, they target different biological pathways and research questions
Nie jest produktem leczniczym, nie jest zatwierdzonym lekiem, nie jest przeznaczony do stosowania u ludzi ani zwierzt i nie zastpuje porady medycznej
However, several indirect considerations are worth noting: Weight loss itself may have beneficial effects on intraocular pressure, with some studies suggesting modest reductions in pressure following significant weight reduction, though evidence is limited and varies between individuals [13] Improved metabolic health from weight loss may benefit overall vascular health, potentially supporting optic nerve perfusion Gastrointestinal side effects (particularly vomiting) could theoretically cause transient pressure spikes due to straining, though this is a theoretical concern not specific to Wegovy or glaucoma patients For patients with diabetic retinopathy , the Wegovy SmPC advises appropriate monitoring when initiating treatment, particularly if rapid glycaemic improvement is anticipated
